Compare Marathon Digital Holdings Inc (MARA) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Marathon Digital Holdings Inc vs Recursion Pharmaceuticals Inc — how do they compare? Marathon Digital Holdings Inc trades at $10.15 (market cap $3.83B), while Recursion Pharmaceuticals Inc trades at $4 (market cap $2.14B). The key difference: Marathon Digital Holdings Inc is the larger of the two by market cap, and Marathon Digital Holdings Inc is more actively traded (47,742,698 versus 30,789,535). Which is the better fit depends on your goals — on Pluang, investors hold Marathon Digital Holdings Inc for 22 Days and Recursion Pharmaceuticals Inc for 22 Days on average.
| MARA | RXRX | |
|---|---|---|
Market Cap | $3.83B | $2.14B |
Volume | 47,742,698 | 30,789,535 |
Sector | Financials | Health |
52-Week High | $22.84 | $6.79 |
52-Week Low | $6.73 | $2.84 |
Typical Hold Time | 22 Days | 22 Days |
Enterprise Value | $5.87B | $1.66B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MARA stock trades at $10.36, down 5.56% today, with a bearish technical signal despite oscillators showing some bullish momentum. The company reported significant losses with a net income margin of -429.71% in 2026, though valuation ratios appear attractive with P/E of 3.37 and EV/EBITDA of 3.31. Recent earnings have consistently missed expectations, with Q2 2026 EPS of -1.60 versus expected 0.17.
The outlook remains challenging due to persistent losses and negative cash flow from operations. Analyst consensus is divided with 45% buy ratings and a $13.25 price target, suggesting 28% upside potential. Key risks include execution challenges, competitive pressures, and reliance on financing activities to sustain operations.
RXRX trades at $4.27, down 7.78% today, with technical indicators showing a bullish trend despite recent weakness. The company reported Q2 2026 earnings miss after two consecutive beats, with revenue declining to $54 million in 2026 from $74 million in 2025. While maintaining a negative net income margin of -961.97%, RXRX continues to expand its AI-powered drug discovery platform through strategic partnerships with Tempus and Roche.
The stock presents high-risk growth potential with strong analyst support (40% buy rating) but faces significant execution challenges. Investment appeal hinges on successful pipeline development and commercialization of AI drug discovery technology, though persistent losses and declining revenue create substantial downside risk for shareholders.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Marathon Digital Holdings Inc
Marathon Digital Holdings, Inc. is one of the largest publicly traded Bitcoin mining companies in North America. The company focuses on building and operating large-scale, cost-efficient Bitcoin mining facilities. Marathon's strategy centers on increasing its mining hash rate and using sustainable energy sources to expand its Bitcoin production. The company's performance is closely tied to the price of Bitcoin and the overall health of the digital asset mining industry.
Read more on MARA →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
